استفاده از پتانسیل درمانی سلول های بنیادی مزانشیمی در درمان سرطان

Harnessing the Therapeutic Potential of Mesenchymal Stem Cells in Cancer Treatment


چاپ صفحه
پژوهان
صفحه نخست سامانه
نویسندگان
نویسندگان
اطلاعات تفضیلی
اطلاعات تفضیلی
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: پریسا کنگری

عنوان کنگره / همایش: کنگره بین المللی زیست پزشکی سرطان و سلولهای بنیادی شیراز , Iran (Islamic Republic) , شیراز , 2024

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله پریسا کنگری
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه مرکز سلولهای بنیادی
کد مقاله 86195
عنوان فارسی مقاله استفاده از پتانسیل درمانی سلول های بنیادی مزانشیمی در درمان سرطان
عنوان لاتین مقاله Harnessing the Therapeutic Potential of Mesenchymal Stem Cells in Cancer Treatment
نوع ارائه سخنرانی
عنوان کنگره / همایش کنگره بین المللی زیست پزشکی سرطان و سلولهای بنیادی شیراز
نوع کنگره / همایش بین المللی
کشور محل برگزاری کنگره/ همایش Iran (Islamic Republic)
شهر محل برگزاری کنگره/ همایش شیراز
سال انتشار/ ارائه شمسی 1403
سال انتشار/ارائه میلادی 2024
تاریخ شمسی شروع و خاتمه کنگره/همایش 1403/09/08 الی 1403/09/09
آدرس لینک مقاله/ همایش در شبکه اینترنت
آدرس علمی (Affiliation) نویسنده متقاضی Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

نویسندگان
hide/show

نویسنده نفر چندم مقاله
پریسا کنگریاول

اطلاعات تفضیلی
hide/show

عنوان متن
کلمات کلیدیMesenchymal stem cells; Cancer therapy; Cell therapy; Exosomes; immunomodulation; Chemotherapeutic agents
خلاصه مقالهCancer, as a complicated disease, is considered to be one of the major leading causes of death globally. Although various cancer therapeutic strategies have been established, however, some issues confine the efficacies of the treatments. In recent decades, biomedical researchers for finding novel and efficient therapeutic solutions have extensively focused on the abilities of stem cells in cancer inhibition. Mesenchymal stem cells (MSCs) are multipotent stromal cells that can the most widely extracted from various sources such as the bone marrow (BM), placenta, umbilical cord (UC), UC blood, menses blood, endometrium, wharton's jelly (WJ), adipose tissue, dental pulp (DP), and amnion. Generally, MSCs are known plastic adherent cells that express surface markers including CD105, CD73, and CD90 and lack the expression of hematopoietic markers such as CD45, CD34, and CD14. These cells are capable of differentiating into osteoblasts, chondrocytes, and adipocytes in vitro. Due to the unique characteristics of MSCs such as paracrine effects, immunomodulation, tumor-tropism, and migration, they are considered promising candidates for cancer therapeutics. Currently, MSCs are an excellent living carrier for delivery of therapeutic genes and chemical agents to target tumor sites. Also, exosomes, the most important extracellular vesicle released from MSCs, act as a strong cell-free tool for cancer therapeutics. MSCs can prevent cancer progression by inhibiting several signaling pathways, such as wnt/β-catenin, PI3K/AKT/mTOR, and JAK/STAT. However, there are several challenges associated with the use of MSCs and their exosomes in the field of therapy that need to be considered. This review explores the significance of MSCs in cell-based therapy, focusing on their homing properties and immunomodulatory characteristics. It also examines the potential of using MSCs as carriers for delivery of anticancer agents and their role in modulating the signal transduction pathways of cancer cells.

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
parisa kangari.pdf1403/09/121550820دانلود
photo_2024-12-02_17-37-37.jpg1403/09/12102671دانلود
photo_2024-12-11_10-59-01.jpg1403/10/0988419دانلود